A Study of MEDI4736 With Tremelimumab in Head and Neck Cancer

To assess safety and tolerability, describe the Dose Limiting Tolerabilities, and determine the Maximum Tolerated Dose (MTD) or the highest protocol defined dose level in the absence of establishing an MTD of MEDI4736 in combination with tremelimumab in subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

January 19, 2016